
    
      The study will be designed as a multi-center, observer-blinded, randomized, placebocontrolled
      phase 1 study in healthy adult subjects of 18 to 65 years of age. A total of 160 healthy male
      and female subjects is planned to be enrolled and randomized in five groups receiving
      different dosages and formulations of IC43 or placebo.
    
  